FDA Ad Division Letter Surge Shows Focus On Prominence Of Risk Information
Executive Summary
An upcoming FDA draft guidance on fair balance in promotional materials could benefit manufacturers following a spate of warning letters from the agency's ad division citing the prominence of risk information
You may also be interested in...
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA's Division of Drug Marketing, Advertising and Communication appears to be shifting the way it writes citations to firms, increasing not just the number of letters it sends, but the number of problems it lists within each letter
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA's Division of Drug Marketing, Advertising and Communication appears to be shifting the way it writes citations to firms, increasing not just the number of letters it sends, but the number of problems it lists within each letter
FDA Objects To Claims Based On Retrospective Analysis In BenzaClin Letter
Sponsors should be wary of constructing advertising claims that move beyond the primary findings of a clinical trial
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: